Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lixte Biotech Hlds (LIXT)

Lixte Biotech Hlds (LIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,103
  • Shares Outstanding, K 7,477
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,590 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.36 +32.63%
on 03/09/26
3.28 -4.57%
on 03/13/26
+0.24 (+8.30%)
since 02/27/26
3-Month
2.36 +32.63%
on 03/09/26
4.10 -23.66%
on 12/29/25
-0.94 (-23.10%)
since 12/26/25
52-Week
0.64 +389.06%
on 06/18/25
6.26 -50.00%
on 09/12/25
+1.86 (+146.46%)
since 03/28/25

Most Recent Stories

More News
Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The...

LIXT : 3.13 (+1.29%)
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core...

LIXT : 3.13 (+1.29%)
LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy...

LIXT : 3.13 (+1.29%)
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various...

LIXT : 3.13 (+1.29%)
LIXTE Biotechnology (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as...

LIXT : 3.13 (+1.29%)
LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its...

LIXT : 3.13 (+1.29%)
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused...

LIXT : 3.13 (+1.29%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor...

LIXT : 3.13 (+1.29%)
LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various...

LIXT : 3.13 (+1.29%)
LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone...

LIXT : 3.13 (+1.29%)

Business Summary

Lixte Biotechnology Holdings Inc. is a drug discovery company which uses biomarker technology to identify enzyme targets associated with serious common diseases. The company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents...

See More

Key Turning Points

3rd Resistance Point 3.63
2nd Resistance Point 3.44
1st Resistance Point 3.26
Last Price 3.13
1st Support Level 2.89
2nd Support Level 2.70
3rd Support Level 2.53

See More

52-Week High 6.26
Fibonacci 61.8% 4.11
Fibonacci 50% 3.45
Last Price 3.13
Fibonacci 38.2% 2.79
52-Week Low 0.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.